Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Antigen Presenting Cells01:22

Antigen Presenting Cells

The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MAGa: Monoclonal Autoimmune Gammopathies.

Cancers·2026
Same author

Regulation of neuronal invasion of small cell lung cancer by STMN2/β-alanine-controlled metabolic reprogramming.

Cell reports·2026
Same author

Seismic reflectivity inversion with mixed L1-L2 norm regularization.

Scientific reports·2025
Same author

Follicular Dendritic Cell Sarcoma in Mediastinum: A Case Study and Literature Review.

The clinical respiratory journal·2025
Same author

[PDZ-binding kinase as a prognostic biomarker for pancreatic cancer: a pan-cancer analysis and validation in pancreatic adenocarcinoma cells].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University·2025
Same author

Comparative and phylogenetic analyses of Stipa L. (Poaceae) species based on the complete chloroplast genome sequences.

BMC plant biology·2025

Related Experiment Video

Updated: May 14, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Dendritic cells in the cancer microenvironment.

Yang Ma1, Galina V Shurin, Zhu Peiyuan

  • 11. Departments of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA;

Journal of Cancer
|February 7, 2013
PubMed
Summary

Tumor microenvironments contain complex immune cells, including dendritic cells (DCs). Understanding DC dysfunction in cancer is crucial for developing new therapies to restore anti-tumor immunity.

Keywords:
dendritic cellsimmunosuppressionregulatory dendritic cellstumor escape.tumor microenvironment

More Related Videos

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Experiment Videos

Last Updated: May 14, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • The tumor immunoenvironment is complex, with diverse immune cells influencing cancer progression.
  • Tumor-induced polarization of immune cells, particularly dendritic cells (DCs), creates a variable and intricate environment.
  • Dendritic cells (DCs) play a critical role in initiating and sustaining anti-tumor immunity, but their function can be compromised within the tumor microenvironment.

Purpose of the Study:

  • To explore the complex roles and functions of dendritic cells (DCs) within the tumor immunoenvironment.
  • To investigate the mechanisms behind DC malfunction and polarization in cancer.
  • To highlight the need for improved therapeutic strategies targeting DC function in cancer patients.

Main Methods:

  • Review of existing literature on tumor immunology and dendritic cell biology.
  • Analysis of studies detailing DC phenotype and function in various cancer types.
  • Examination of signaling pathways implicated in DC polarization and dysfunction.

Main Results:

  • Dendritic cells (DCs) exhibit diverse functions, including both pro-tumorigenic and anti-tumorigenic activities within the tumor microenvironment.
  • Tumor-associated factors can lead to the loss or inefficiency of DC antigen-presenting capabilities.
  • DCs can be polarized into immunosuppressive regulatory DCs, promoting tumor growth and progression by limiting effector T cell activity.

Conclusions:

  • Dysfunctional dendritic cells (DCs) contribute significantly to tumor progression and immune evasion.
  • Current therapeutic approaches lack effective strategies to prevent or reverse DC malfunction in cancer.
  • A deeper understanding of dendritic cell (DC) immunobiology in cancer is essential for developing novel and effective immunotherapies.